Dan Coats Looking Into EpiPen Pricing
On Tuesday, Senator Dan Coats (R-Ind.) joined Senate Finance Committee Republicans in sending a letter to Department of Health and Human Services (HHS) Inspector General (IG) Daniel R. Levinson requesting information about the process and oversight involved in determining EpiPen pricing. In their letter, the senators wrote, “Manufacturer rebates play an important role in helping to offset the ever-increasing costs of prescription drugs to the Medicaid program. The recent controversy surrounding Mylan’s prescription drug product EpiPen raises questions about the controls in place to ensure that drug manufacturers are paying appropriate rebates. A thorough and timely review of these issues by the Office of the Inspector General will provide important information to Congress about how CMS is overseeing this significant part of the Medicaid program and where changes in policy need to be made to protect the program against these types of vulnerabilities in the future.”
Leave a Reply
You must be logged in to post a comment.